BERKELEY HEIGHTS, N.,J., April 26, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) today announced that the Company has initiated a new clinical trial of tesetaxel in Japan as part of a comprehensive new initiative. Tesetaxel, the leading oral taxane in clinical development, will be evaluated over a limited dosing-range as a single agent in patients with advanced cancer. The new trial will be conducted at Kinki University in Osaka, which will enable the next generation of clinical studies in Japan.
